share_log

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

HC Wainwright & Co. Reiterates Buy on BioLine Rx, Maintains $21 Price Target

HC Wainwright & Co.重申在BioLine Rx上买入,维持21美元的目标股价
Benzinga ·  2024/05/29 22:24

HC Wainwright & Co. analyst Joseph Pantginis reiterates BioLine Rx (NASDAQ:BLRX) with a Buy and maintains $21 price target.

HC Wainwright & Co. 分析师Joseph Pantginis重申买入bioline rx(NASDAQ:BLRX),并维持21美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发